Gossamer Bio (GOSS) Revenue & Revenue Breakdown
Gossamer Bio Revenue Highlights
Latest Revenue (Y)
$48.47M
Latest Revenue (Q)
$13.29M
Gossamer Bio Revenue by Period
Gossamer Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $48.47M | -57.74% |
| 2024-12-31 | $114.70M | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | - |
Gossamer Bio generated $48.47M in revenue during NA 2025, up -57.74% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Gossamer Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $13.29M | 15.71% |
| 2025-06-30 | $11.49M | 16.18% |
| 2025-03-31 | $9.89M | 5.44% |
| 2024-12-31 | $9.38M | -1.07% |
| 2024-09-30 | $9.48M | -90.11% |
| 2024-06-30 | $95.84M | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $6.78M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Gossamer Bio generated $13.29M in revenue during Q3 2025, up 15.71% compared to the previous quarter, and up 13.87% compared to the same period a year ago.
Gossamer Bio Revenue Breakdown
Gossamer Bio Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 |
|---|---|---|
| License and Service | - | $90.68M |
Latest
Quarterly Revenue by Product
| Product/Service | Sep 25 | Jun 25 | Sep 24 |
|---|---|---|---|
| License and Service | - | - | - |
Latest
Gossamer Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RIGL | Rigel Pharmaceuticals | $294.28M | $69.46M |
| RGNX | REGENXBIO | $170.44M | $29.73M |
| LXRX | Lexicon Pharmaceuticals | $49.80M | $14.18M |
| GOSS | Gossamer Bio | $48.47M | $13.29M |
| PRTA | Prothena | $9.68M | $2.42M |
| CRVS | Corvus Pharmaceuticals | - | - |
| RAPT | RAPT Therapeutics | - | - |
| VTYX | Ventyx Biosciences | - | - |
| FDMT | 4D Molecular Therapeutics | - | - |
| KALV | KalVista Pharmaceuticals | - | $13.69M |
| OLMA | Olema Pharmaceuticals | - | - |